Pfizer, BioNTech, and Moderna are making thousands of dollars per minute from the COVID-19 vaccine, but less than 1% of each company’s dose goes to the world’s poorest countries, according to a new analysis from the People’s Vaccine Alliance. It has been. (PVA).
PVA is a coalition of organizations campaigning for broader access to the COVID-19 vaccine and is calculated based on the company’s latest corporate report.
The Alliance estimates that the trio will make $ 34 billion in pre-tax profits among them this year, which can be $ 1,000 per second, $ 65,000 per minute, or $ 93.5 million per day. In total, the three billionaire owners have a net worth of $ 35.1 billion.
According to PVA, both companies sell most of their vaccine doses to wealthy countries, while low-income countries remain inadequately vaccinated.
Pfizer and BioNTech provide less than 1% of the total vaccine supply to low-income countries, while Modana provides only 0.2%, PVA said. On the other hand, 98 percent of people in low-income countries are not fully vaccinated.
“It’s sneaky that only 2% of people in low-income countries are completely vaccinated against the coronavirus, while only a few companies make millions of dollars every hour.” Said Maaza Seyoum of the African Alliance and the People’s Vaccine Alliance Africa. Said. “Pfizer, BioNTech and Modana used their monopoly to prioritize the most profitable contracts with the wealthiest governments and leave low-income countries in the cold.”
Despite PVA receiving over $ 8 billion in public funding, Pfizer, BioNTech and Moderna have stated that “Vaccine technology to competent producers in low- and middle-income countries through the World Health Organization (WHO).” I refused the call to urgently transfer know-how. ” “We can increase global supply, lower prices and save millions of lives,” he said.
The Epoch Times is seeking comment from Pfizer, BioNTech and Moderna.
In September, WHO Director Tedros Adhanomgebreyes urged countries to postpone the provision of COVID-19 booster shots until September so that poor countries could provide their citizens with the first dose of the vaccine. ..
WHO Director General told reporters that in some low-income countries, including much of Africa, less than 2 percent of the adult population is fully vaccinated. In contrast, in some high-income countries, adult immunization rates are 50%.
PVA specifically called on Moderna and was pressured to work with both the White House and WHO to help accelerate plans to share technology to replicate Moderna vaccines for broader production at South African mRNA hubs. Said that.
In October, Moderna announced the availability of up to 110 million COVID-19 vaccines in African countries.
Last May, Pfizer CEO Albert Bourla described the idea of sharing intellectual property rights and vaccine recipes as “nonsense” and even “dangerous,” but PVA said earlier this month Indian vaccines. WHO Emergency Use Approval for Covacine “Developing countries have the capacity and expertise.”
The three companies are reportedly expected to make billions of dollars in total this year, while vaccine makers AstraZeneca and Johnson & Johnson are providing vaccines on a non-profit basis, but recently both have We have announced plans to end this arrangement in the future.
Jennifer Taubert, head of Johnson & Johnson’s pharmaceutical division, told reporters in October that the company Enter the commercial market At the end of 2022 or the beginning of 2023.
Meanwhile, pharmaceutical company AstraZeneca announced last week plans to start selling shots with “moderate profitability.”
On Monday, a group backed by Pfizer and the United Nations announced that pharmaceutical companies would have external companies manufacture COVID-19 pills.
“Pfizer continues to work to bring scientific breakthroughs to end this pandemic for all. Oral antiviral treatment reduces the severity of COVID-19 infections and the medical system. We believe it can play an important role in reducing the burden on people and saving lives, “Bourla said in a statement.
Although the pill has not yet been approved in any country, studies have shown that Pfizer is highly effective in reducing the risk of hospitalization or death if given within 3 days of symptomatic COVID. Immediately after this, we will seek an emergency use authorization from the US drug regulatory authority. 19.